Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

OBJECTIVE: To compare the effectiveness of meropenem with imipenem plus cilastatin in the treatment of severe infections. DATA SOURCES: CENTRAL, EMBASE and MEDLINE were searched for abstracts and papers. All searching was completed in March 2004. No restriction was placed on language. STUDY SELECTI...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Edwards, S, Emmas, C, Campbell, H
Formato:	Journal article
Idioma:	English
Publicado em:	2005

Registros relacionados

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
por: Edwards, S, et al.
Publicado em: (2006)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
por: Xi You, et al.
Publicado em: (2024-03-01)

Retrospective evaluation of piperacillin–tazobactam, imipenem–cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia
por: Eman Youssif, et al.
Publicado em: (2018-07-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
por: Pasquale Sansone, et al.
Publicado em: (2024-05-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
por: Hiroki Nakamura, et al.
Publicado em: (2024-03-01)

Effect of Oxygen and Water on the Stability of Imipenem and Cilastatin Sodium for Injection
por: Meng Zhang, et al.
Publicado em: (2022-06-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
por: Alex A. Erasmo
Publicado em: (2004-07-01)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
por: Maria Agudelo, et al.
Publicado em: (2019-01-01)

The Pattern of Imipenem/Cilastatin Administration in Imam Khomeini Hospital (Ardabil) in 2018
por: Moien Zakavati, et al.
Publicado em: (2019-04-01)

Corrigendum to “Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients” [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]
por: Xi You, et al.
Publicado em: (2024-03-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
por: Ryan K. Shields, et al.
Publicado em: (2024-06-01)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Takahiro Arima, et al.
Publicado em: (2022-01-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Mona I. Shaaban, et al.
Publicado em: (2017-04-01)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara WK, et al.
Publicado em: (2015-03-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
por: Paul Laffont-Lozes, et al.
Publicado em: (2024-10-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Jaesh Naik, et al.
Publicado em: (2023-01-01)

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin
por: Yanna Zhu, et al.
Publicado em: (2020-03-01)

A Prospective Randomized Trial of Imipenem-Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra-Abdominal and Pelvic Infections
por: Lionel A Mandell, et al.
Publicado em: (1993-01-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
por: Shakila Baei Lashaki, et al.
Publicado em: (2025-05-01)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
por: Islam M Ghazi, et al.
Publicado em: (2020-01-01)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
por: Chang-Hua Chen, et al.

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
por: Faezeh Milani, et al.
Publicado em: (2023-09-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
por: Takaki Hirano, et al.
Publicado em: (2022-12-01)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
por: Xiaokui Huo, et al.
Publicado em: (2019-09-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
por: I. I. Shteynberg, et al.
Publicado em: (2015-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation
por: C Kani, et al.
Publicado em: (2005-06-01)

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
por: Chen Xiaoping, et al.
Publicado em: (2010-07-01)

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material
por: Sakiko Hiraki, MD, et al.
Publicado em: (2023-09-01)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
por: E. Dahdouh, et al.
Publicado em: (2014-01-01)

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa
por: Glenn J. Rapsinski, et al.
Publicado em: (2025-03-01)

Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report
por: A. B. Strok, et al.
Publicado em: (2024-01-01)

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection
por: A. K. Chaudhary, et al.
Publicado em: (2010-01-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
por: Telma de Sousa, et al.
Publicado em: (2023-11-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
por: Sakiko Hiraki, et al.
Publicado em: (2023-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation
por: Kani C., et al.
Publicado em: (2005-07-01)

Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
por: George G Zhanel, et al.
Publicado em: (1998-01-01)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
por: Hassuna NA, et al.
Publicado em: (2020-01-01)

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
por: Peng Jia, et al.
Publicado em: (2025-02-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
por: Qingxin Yang, et al.
Publicado em: (2023-12-01)

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
por: Hazhir Moradi, et al.
Publicado em: (2024-12-01)